Last reviewed · How we verify
Interleukin-3
Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages.
Interleukin-3 is a cytokine that stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells, promoting the production of multiple blood cell lineages. Used for Bone marrow failure syndromes, Myelodysplastic syndromes, Aplastic anemia.
At a glance
| Generic name | Interleukin-3 |
|---|---|
| Sponsor | Sandoz |
| Drug class | Cytokine |
| Target | IL-3 receptor (CD123) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | FDA-approved |
Mechanism of action
IL-3 acts as a growth factor for bone marrow stem cells and early progenitor cells, enhancing the development of myeloid and lymphoid cell lines. It works by binding to the IL-3 receptor on target cells, triggering signaling cascades that increase cell proliferation, differentiation, and survival. This mechanism makes it useful for stimulating blood cell recovery in patients with compromised bone marrow function.
Approved indications
- Bone marrow failure and aplastic anemia
- Myelodysplastic syndromes
- Chemotherapy-induced myelosuppression
Common side effects
- Fever
- Bone pain
- Myalgia
- Headache
- Injection site reactions
Key clinical trials
- Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant (PHASE1)
- Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (PHASE2)
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (PHASE1, PHASE2)
- Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE1, PHASE2)
- Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant (PHASE2)
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia (PHASE1)
- AOA in Recurrent Fertilization Failure (PHASE4)
- DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interleukin-3 CI brief — competitive landscape report
- Interleukin-3 updates RSS · CI watch RSS
- Sandoz portfolio CI